Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Brii Biosciences Limited BRIBF OTC

Other OTC • Healthcare • Biotechnology • CN • USD

SharesGrow Score
27/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Brii Biosciences Limited (BRIBF) is a Biotechnology company in the Healthcare sector, currently trading at $0.19. It has a SharesGrow Score of 25/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $18M, +2610.3%/yr average growth. Net income is $217M (loss), growing at -24%/yr. Net profit margin is -1196.6% (negative). Gross margin is 0% (-100 pp trend).

Balance sheet: total debt is $9M against $2.4B equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 60.73 (strong liquidity). Debt-to-assets is 0.4%. Total assets: $2.4B.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 0/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

BRIBF SharesGrow Score Overview

45/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BRIBF

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
BRIBF: +2610.3%/yr revenue is, -24%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet BRIBF: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 60.73 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
—
MOAT N/A
N/A
No analyst coverage available for this stock.
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
BRIBF: Net profit margin is -1196.6%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.18671-0.3042
Volume4.15K
Avg Volume (30D)2.05K
Market Cap$135.65M
Beta (1Y)1.30
Share Statistics
EPS (TTM)-0.30
Shares Outstanding$721.87M
IPO Date2022-01-21
Employees98
CEOZhi Hong
Financial Highlights & Ratios
Revenue (TTM)$18.12M
EBITDA$-290.31M
Net Income$-216.88M
Operating Income$-295.91M
Total Cash$1.94B
Total Debt$8.93M
Net Debt$-599.75M
Total Assets$2.36B
Price / Earnings (P/E)-0.6
Price / Sales (P/S)7.48
Analyst Forecast
Company Info
CountryCN
ExchangeOther OTC
CurrencyUSD
ISINKYG1645A1094

Price Chart

Track all markets on TradingView
BRIBF
Brii Biosciences Limited ↗  ·  Other OTC
Healthcare • Biotechnology
0.19 52WK RANGE 0.30

People Also View

INCY
INCY
Incyte Corporation
$97.10
-0.60%
 AXSM
AXSM
Axsome Therapeutics, Inc.
$184.18
+0.07%
 IMGN
IMGN
ImmunoGen, Inc.
$31.24
+0.02%
 MIRM
MIRM
Mirum Pharmaceuticals, Inc.
$96.40
-0.52%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.71
+0.06%
 AKRO
AKRO
Akero Therapeutics, Inc.
$54.65
+0.00%
 ACAD
ACAD
ACADIA Pharmaceuticals Inc.
$21.76
-1.18%
 SRPT
SRPT
Sarepta Therapeutics, Inc.
$21.73
-1.90%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message